Where We Stand on Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
نویسندگان
چکیده
منابع مشابه
Where We Stand on Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation.
PURPOSE OF REVIEW Anticoagulant therapy effectively reduces the incidence of stroke in patients with atrial fibrillation (AF) but is underutilized and frequently contraindicated. The left atrial appendage (LAA) is the primary site of thrombus formation in AF patients. Surgical and percutaneous appendage closure has been evaluated as a site-specific therapy to reduce systemic thromboembolism. ...
متن کاملLeft Atrial Appendage Exclusion for Stroke Prevention in Atrial Fibrillation
The public health burden of atrial fibrillation (AF) and associated thromboembolic stroke continues to grow at alarming rates. AF leads to a fivefold increase in the risk of stroke. Therefore, stroke prevention remains the most critical aspect of AF management. Current standard of care focuses on oral systemic anticoagulation, most commonly with warfarin and now with newer agents such as dabiga...
متن کاملPost-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation.
BACKGROUND Left atrial appendage closure (LAAC) was approved by the U.S. Food and Drug Administration (FDA) as a stroke prevention alternative to warfarin for patients with nonvalvular atrial fibrillation. However, clinical decision-making is confounded by the fact that although LAAC attenuates the anticoagulant-related lifetime risk of bleeding, implantation is associated with upfront complica...
متن کاملLeft atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation.
Atrial fibrillation is a frequent cause of stroke; in the elderly, more than 20% of strokes are attributed to this common arrhythmia. Anticoagulation with warfarin reduces the risk of stroke by ∼60%; however, a large proportion of patients with atrial fibrillation do not receive this treatment because of relative/absolute contraindications. Moreover, patients often discontinue warfarin for a va...
متن کاملPROTECT AF trial: left atrial appendage closure device (Watchman) for stroke prevention in atrial fibrillation
Holmes and the investigators of the PROTECT AF trial present the results of a randomized multicenter study a ssessing the noninferiority of the Watchman (Atritech, MN, USA) LAA occlusion device versus chronic warfarin therapy. The Watchman device is a percutaneously and trans-septally delivered, self-expanding device to seal the LAA ostium. A total of 707 patients were random ized in a 2:1 fash...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Texas Heart Institute Journal
سال: 2016
ISSN: 0730-2347,1526-6702
DOI: 10.14503/thij-16-5811